Dublin, Ireland

Matthew Allister Lambert

USPTO Granted Patents = 3 

Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovation and Impact: The Achievements of Matthew Allister Lambert

Introduction: Matthew Allister Lambert is a distinguished inventor based in Dublin, Ireland, known for his groundbreaking work in the field of biotechnology. With a total of three patents to his name, Lambert has significantly contributed to our understanding and application of antibodies, particularly in relation to GDF15.

Latest Patents: Among his latest innovations, Lambert has developed the Anti-GDF15 antibodies, compositions, and methods of use. This invention provides antibodies and antigen-binding fragments that specifically bind to GDF15, opening up new avenues for therapeutic applications and research in this area.

Career Highlights: Lambert currently works at Pfizer Corporation, a leading pharmaceutical company known for its innovative approach to drug development and healthcare solutions. His research efforts have placed him at the forefront of biochemical advancements, contributing to more effective treatments and therapies.

Collaborations: Throughout his career, Lambert has collaborated with notable colleagues, including James Reasoner Apgar and Kevin Charles Beaumont. These partnerships have further enhanced his work, allowing for the exchange of ideas and fostering advancements in their respective fields.

Conclusion: Matthew Allister Lambert exemplifies the spirit of innovation within the biotechnology sector. His contributions, particularly in the development of Anti-GDF15 antibodies, are a testament to his expertise and dedication, promising to impact the future of medical science significantly. As he continues his work at Pfizer Corporation, the potential for more groundbreaking inventions remains high.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…